Group Analysis - Stock Erreur-404

INDUSTRY ANALYSIS

🏭

Biotechnology

MOST VOLATILE ASSET

$MRNA -16.47%

AI Accuracy

0%

71 Events Tracked

Net Profit (Fixed)

0

$100 Base / Trade

Compound Balance

0

Reinvested Profits

📈 Group Equity Curve ($1000 Base)

🧠 AI Sentiment Distribution

🏢 Constituents

Asset ↕	Events ↕	Win Rate ↕	Net PnL ↕
VRTXVertex Pharmaceuticals In	13	38%	+$23
ALNYAlnylam Pharmaceuticals,	1	0%	+$0
BMRNBioMarin Pharmaceutical I	1	0%	+$0
HALOHalozyme Therapeutics, In	1	0%	+$0
JAZZJazz Pharmaceuticals plc	1	0%	+$0
CYTKCytokinetics, Incorporate	1	0%	+$0
INSMInsmed Incorporated	1	0%	+$0
ARWRArrowhead Pharmaceuticals	1	0%	+$0
EXELExelixis, Inc.	1	0%	+$0
MRNAModerna, Inc.	13	46%	$-7
TECHBio-Techne Corp	12	17%	$-7
REGNRegeneron Pharmaceuticals	13	15%	$-8
INCYIncyte Corporation	12	8%	$-12

📰 LATEST AI REPORTS: BIOTECHNOLOGY

A Neutral Perspective on MRNA’s Q1 Earnings: What Investors Should Watch

MRNA’s Q1 Earnings Report: A Neutral Position Until the Market Reacts

Market Analysis: Top Trading Opportunities in 2026